Tchem UBE2D3 Ubiquitin-conjugating enzyme E2 D3

Protein Summary

Description

Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins. In vitro catalyzes 'Lys-11'-, as well as 'Lys-48'-linked polyubiquitination. Cooperates with the E2 CDC34 and the SCF(FBXW11) E3 ligase complex for the polyubiquitination of NFKBIA leading to its subsequent proteasomal degradation. Acts as an initiator E2, priming the phosphorylated NFKBIA target at positions 'Lys-21' and/or 'Lys-22' with a monoubiquitin. Ubiquitin chain elongation is then performed by CDC34, building ubiquitin chains from the UBE2D3-primed NFKBIA-linked ubiquitin. Acts also as an initiator E2, in conjunction with RNF8, for the priming of PCNA. Monoubiquitination of PCNA, and its subsequent polyubiquitination, are essential events in the operation of the DNA damage tolerance (DDT) pathway that is activated after DNA damage caused by UV or chemical agents during S-phase. Associates with the BRCA1/BARD1 E3 ligase complex to perform ubiquitination at DNA damage sites following ionizing radiation leading to DNA repair. Targets DAPK3 for ubiquitination which influences promyelocytic leukemia protein nuclear body (PML-NB) formation in the nucleus. In conjunction with the MDM2 and TOPORS E3 ligases, functions ubiquitination of p53/TP53. Supports NRDP1-mediated ubiquitination and degradation of ERBB3 and of BRUCE which triggers apoptosis. In conjunction with the CBL E3 ligase, targets EGFR for polyubiquitination at the plasma membrane as well as during its internalization and transport on endosomes. In conjunction with the STUB1 E3 quality control E3 ligase, ubiquitinates unfolded proteins to catalyze their immediate destruction. The modification of proteins with ubiquitin is an important cellular mechanism for targeting abnormal or short-lived proteins for degradation. Ubiquitination involves at least three classes of enzymes: ubiquitin-activating enzymes, or E1s, ubiquitin-conjugating enzymes, or E2s, and ubiquitin-protein ligases, or E3s. This gene encodes a member of the E2 ubiquitin-conjugating enzyme family. This enzyme functions in the ubiquitination of the tumor-suppressor protein p53, which is induced by an E3 ubiquitin-protein ligase. [provided by RefSeq, Jan 2017]

Uniprot Accession IDs

• P61077
• A6NJ93
• A6NJB1
• A6NM99
• P47986
• Q6IB88
• Q6NXS4
• Q8N924

Gene Name

• UBE2D3

Ensembl ID

• ENST00000321805
• ENSP00000318494
• ENSG00000109332
• ENST00000338145
• ENSP00000337208
• ENST00000343106
• ENSP00000345285
• ENST00000349311
• ENSP00000344069
• ENST00000357194
• ENSP00000349722
• ENST00000394801
• ENSP00000378280
• ENST00000394803
• ENSP00000378282
• ENST00000394804
• ENSP00000378283
• ENST00000453744
• ENSP00000396901

Symbol

• UBC5C
• UBCH5C
• UBC4/5
• UBCH5C
• E2(17)KB3

Knowledge Table

Most Knowledge About	Knowledge Value (0 to 1 scale)
disease perturbation	1
virus perturbation	1
transcription factor perturbation	0.98
kinase perturbation	0.95
biological process	0.93

Protein Classes

PANTHER Classes

Protein / Ligase / Ubiquitin-conjugating Enzyme E2 D3

DTO Classes

Protein / Enzyme / Ligase / Ubiquitin-conjugating Enzyme E2 D3

IDG Development Level Summary

Tdark

These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 45.79   (req: < 5)

Gene RIFs: 22   (req: <= 3)

Antibodies: 202   (req: <= 50)

Tbio

These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 45.79   (req: >= 5)

Gene RIFs: 22   (req: > 3)

Antibodies: 202   (req: > 50)

- OR - satisfy the following criterion:

Gene Ontology Terms: 19

Tchem

Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions

Active Ligands: 2

Tclin

Target has at least one approved drug - AND - satisfies the preceding conditions

Active Drug: 0